These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 19018722)
1. Malignant hyperthermia: a pharmacogenetic disorder. Stowell KM Pharmacogenomics; 2008 Nov; 9(11):1657-72. PubMed ID: 19018722 [TBL] [Abstract][Full Text] [Related]
2. Identification and biochemical characterization of a novel ryanodine receptor gene mutation associated with malignant hyperthermia. Anderson AA; Brown RL; Polster B; Pollock N; Stowell KM Anesthesiology; 2008 Feb; 108(2):208-15. PubMed ID: 18212565 [TBL] [Abstract][Full Text] [Related]
3. Malignant hyperthermia: an inherited disorder of skeletal muscle Ca+ regulation. Louis CF; Balog EM; Fruen BR Biosci Rep; 2001 Apr; 21(2):155-68. PubMed ID: 11725864 [TBL] [Abstract][Full Text] [Related]
4. Intracellular calcium homeostasis in human primary muscle cells from malignant hyperthermia-susceptible and normal individuals. Effect Of overexpression of recombinant wild-type and Arg163Cys mutated ryanodine receptors. Censier K; Urwyler A; Zorzato F; Treves S J Clin Invest; 1998 Mar; 101(6):1233-42. PubMed ID: 9502764 [TBL] [Abstract][Full Text] [Related]
5. Mild clinical and histopathological features in patients who carry the frequent and causative malignant hyperthermia RyR1 mutation p.Thr2206Met. Rueffert H; Wehner M; Ogunlade V; Meinecke C; Schober R Clin Neuropathol; 2009; 28(6):409-16. PubMed ID: 19919814 [TBL] [Abstract][Full Text] [Related]
6. Novel double and single ryanodine receptor 1 variants in two Austrian malignant hyperthermia families. Kaufmann A; Kraft B; Michalek-Sauberer A; Weindlmayr M; Kress HG; Steinboeck F; Weigl LG Anesth Analg; 2012 May; 114(5):1017-25. PubMed ID: 22415532 [TBL] [Abstract][Full Text] [Related]
7. Ryanodine receptor mutations in malignant hyperthermia and central core disease. McCarthy TV; Quane KA; Lynch PJ Hum Mutat; 2000; 15(5):410-7. PubMed ID: 10790202 [TBL] [Abstract][Full Text] [Related]
8. Frequency and localization of mutations in the 106 exons of the RYR1 gene in 50 individuals with malignant hyperthermia. Galli L; Orrico A; Lorenzini S; Censini S; Falciani M; Covacci A; Tegazzin V; Sorrentino V Hum Mutat; 2006 Aug; 27(8):830. PubMed ID: 16835904 [TBL] [Abstract][Full Text] [Related]
16. [Biology of malignant hyperthermia: a disease of the calcium channels of the skeletal muscle]. Monnier N; Lunardi J Ann Biol Clin (Paris); 2000; 58(2):147-56. PubMed ID: 10760701 [TBL] [Abstract][Full Text] [Related]
17. Malignant hyperthermia: clinical and molecular aspects. Correia AC; Silva PC; da Silva BA Rev Bras Anestesiol; 2012; 62(6):820-37. PubMed ID: 23176990 [TBL] [Abstract][Full Text] [Related]
18. Pharmacogenetics and pathophysiology of CACNA1S mutations in malignant hyperthermia. Beam TA; Loudermilk EF; Kisor DF Physiol Genomics; 2017 Feb; 49(2):81-87. PubMed ID: 28011884 [TBL] [Abstract][Full Text] [Related]
19. Ryanodine receptor type 1 gene mutations found in the Canadian malignant hyperthermia population. Kraeva N; Riazi S; Loke J; Frodis W; Crossan ML; Nolan K; Kraev A; Maclennan DH Can J Anaesth; 2011 Jun; 58(6):504-13. PubMed ID: 21455645 [TBL] [Abstract][Full Text] [Related]
20. Functional studies of RYR1 mutations in the skeletal muscle ryanodine receptor using human RYR1 complementary DNA. Sato K; Pollock N; Stowell KM Anesthesiology; 2010 Jun; 112(6):1350-4. PubMed ID: 20461000 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]